Macrophage Pharma Ltd (MPL) is a leading UK innate immune cell company focused on treating human diseases involving regulated cell death. Macrophage Pharma’s novel approach utilizes its proprietary cell selective small molecule Esterase Sensitive Motif™ (ESM) platform to target key pathways involved in regulated cell death.
ESM™ is clinically validated, delivering drugs to cells of myeloid origin with exquisite selectivity resulting in improved pharmacology, efficacy, and safety. The approach provides opportunity for both best-in-class drugs against validated targets and first-in-class molecules for highly novel targets.
MPL leadership comprises a highly experienced executive team with a strong entrepreneurial track record in biopharma, a Board of Directors featuring leading figures from the investment community and a Scientific Advisory Board which includes both world class immunologists and oncologists. Together, these capabilities provide MPL with the foundations to deliver novel therapies through high impact science and strong commercial awareness.
For more information, please visit the company website: www.macrophagepharma.com
ESM™ is clinically validated, delivering drugs to cells of myeloid origin with exquisite selectivity resulting in improved pharmacology, efficacy, and safety. The approach provides opportunity for both best-in-class drugs against validated targets and first-in-class molecules for highly novel targets.
MPL leadership comprises a highly experienced executive team with a strong entrepreneurial track record in biopharma, a Board of Directors featuring leading figures from the investment community and a Scientific Advisory Board which includes both world class immunologists and oncologists. Together, these capabilities provide MPL with the foundations to deliver novel therapies through high impact science and strong commercial awareness.
For more information, please visit the company website: www.macrophagepharma.com
Location: United Kingdom, England, Windsor
Employees: 11-50
Founded date: 2014
Investors 2
| Date | Name | Website |
| 08.11.2022 | M Ventures | m-ventures... |
| - | Aglaia Onc... | aglaia-onc... |
Mentions in press and media 3
| Date | Title | Description |
| 24.08.2017 | Term Sheet — Thursday, August 24 | A BUGABOO Earlier this week, I mentioned that Jim Clark is back with a new building security startup based in Del Rey, Fla., called CommandScape. One key element to the startup’s product is that its building management “command center” will... |
| 23.08.2017 | Macrophage Pharma Extends Series A Funding Round | Macrophage Pharma Limited, a Windsor, England, UK-based immuno-oncology research and development company focused on macrophage modulation in the tumour microenvironment (TME), raised additional funding from Merck Ventures to complete the Se... |
| 09.01.2017 | Macrophage Pharma Raises £9M in Series A Financing | Macrophage Pharma Limited, a Windsor, UK-based immune-oncology company, raised £9m in Series A equity financing. The round was led by CRT Pioneer Fund with participation from Novo Seeds, part of Novo A/S, and Aglaia Biomedical Ventures. The... |